Navigation Links
Bard Dermal Allograft

ProductsBard Dermal Allograft
Company C. R. Bard, Inc.
Item Bard Dermal Allograft
Features 
  • All tissue undergoes donor screening, serologic and microbiologic testing which meet or exceed guidelines and standards established by the U.S. Food and Drug Administration as well as local and state requirements.
  • Bard Dermal Allograft implant maintains the density of the original collagen structure with minimal destruction of fibrils (determined by biomechanical and enzymatic testing).
  • Bard Dermal Allograft is processed using a patent-pending method that helps promote fibroblast infiltration and generation of host collagen within the implant.
  • Quality screening test confirms that collagen fibrils are intact to ensure durability and longevity.
  • Confirms no bacterial growth.
Description Meets the demanding requirements of most pelvic floor reconstructive procedures, and is highly resistant to suture pull-through, demonstrating long-term durability, and serves as a structural support for effective ingrowth of the hosts collagen.
Info C. R. Bard, Inc.
Customer Service: (800) 367-2273
Web site: http://www.crbard.com

Related medicine products :

1. Bard® Dermal Allograft
2. SilkPeel Dermalinfusion
3. Restylane® Hyaluronic Acid Dermal Filler
4. Captique™ Hyaluronic Acid Dermal Filler
5. IBS® Allograft Lumbar
6. Connect Cervical Allografts System
7. Puros Allografts
8. VG1 ALIF Allograft
9. VG2 PLIF Allograft
10. Corlok Lumbar Allograft System
11. Duet Lumbar Allograft System
Other Medicine News:Health News:FDA Approves Luvox(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD) 2Health News:FDA Approves Luvox(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD) 3Health News:FDA Approves Luvox(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD) 4Health News:FDA Approves Luvox(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD) 5Health News:FDA Approves Luvox(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD) 6Health News:Heart Hormones Beat Back Cancers in Mice 2Health News:Heart Hormones Beat Back Cancers in Mice 3Health News:Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results 2Health News:Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results 3Health News:Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results 4Health News:Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results 5Health News:Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results 6Health News:$50 million gift to NewYork-Presbyterian Hospital/Weill Cornell Medical Center 2Health News:$50 million gift to NewYork-Presbyterian Hospital/Weill Cornell Medical Center 3Health News:$50 million gift to NewYork-Presbyterian Hospital/Weill Cornell Medical Center 4Health News:$50 million gift to NewYork-Presbyterian Hospital/Weill Cornell Medical Center 5Health News:Plastic Surgeon Joins Established Practice 2
Breaking Medicine Technology:OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 2Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 3Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 4Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 5Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 7Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 8Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 9Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 10Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 11Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 12Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 13Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 14Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 2Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 3Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 4Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 5Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level 13358 1Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level 13358 2Midlife Heart Risk Factors Linked to Later Dementia 53613 1Midlife Heart Risk Factors Linked to Later Dementia 53613 2Midlife Heart Risk Factors Linked to Later Dementia 53613 3More Than One in Five 12 to 17 Year Olds Have Trouble Seeing in Class 53609 1More Than One in Five 12 to 17 Year Olds Have Trouble Seeing in Class 53609 2More Than One in Five 12 to 17 Year Olds Have Trouble Seeing in Class 53609 3More Than One in Five 12 to 17 Year Olds Have Trouble Seeing in Class 53609 4